MedTrace Logo

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

NCT03984565 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-03-30

No results posted yet for this study

Summary

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.

Conditions

Interventions

DRUG

Cannabidiol

High-CBD, low-THC sublingual product formulated in palm oil

DRUG

Placebo

Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.

Sponsors & Collaborators

  • Etheridge Foundation

    collaborator UNKNOWN

  • Staci Gruber, Ph.D.

    lead OTHER

Principal Investigators

  • Staci Gruber, Ph.D. · Mclean Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-27
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984565 on ClinicalTrials.gov